Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Efficacy and safety of capmatinib plus pembrolizumab in treatment (tx) -nave patients with advanced nonsmall cell lung cancer (NSCLC) with high tumor PD-L1 expression: Results of a randomized, open-label, mult icenter, phase 2 study
By engaging both receptor systems at once, tirzepatide can produce a stronger combined effect on appetite, blood sugar regulation, and body weight than single-hormone medications typically achieve
After a drug launches, our independent Pharmacy & Therapeutics (P&T) Committee reviews clinical and safety information and provides recommendation for formulary inclusion
Sinning I, Kleywegt GJ, Cowan SW, Reinemer P, Dirr HW, Huber R, et al
It's a reimbursement program
US$ 22.83
US$ 21.87
US$ 24.40
US$ 23.97
US$ 26.56
US$ 29.18
US$ 22.02
